Tesamorelin Therapy in Miami, FL

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic hormone that signals the pituitary gland to produce and release human growth hormone (HGH). It is marketed under the brand name Egrifta and holds the distinction of being the only GHRH analog with FDA approval specifically for the reduction of visceral abdominal fat.

Tesamorelin was originally developed and approved for the treatment of lipodystrophy in HIV-positive patients — a condition characterized by abnormal fat accumulation in the trunk and abdomen. Clinical trials demonstrated that tesamorelin significantly reduced visceral adipose tissue (VAT) in this population, and its efficacy has led to growing off-label use in the broader anti-aging and body composition optimization space.

At Rewind Anti-Aging of Miami, we prescribe tesamorelin for patients who want to specifically target visceral abdominal fat — the deep, metabolically active fat that surrounds the organs and drives cardiovascular risk, insulin resistance, and systemic inflammation.

Why Visceral Fat Matters

Not all body fat is equal. Subcutaneous fat — the fat you can pinch beneath the skin — is relatively benign from a health perspective. Visceral fat — the fat that accumulates deep in the abdominal cavity, surrounding the liver, intestines, and other organs — is a different story entirely.

Visceral fat is metabolically active tissue that functions almost like an endocrine organ, releasing inflammatory cytokines, hormones, and other bioactive compounds that contribute to:

• Insulin resistance and type 2 diabetes — visceral fat impairs insulin signaling and glucose metabolism
• Cardiovascular disease — the inflammatory molecules released by visceral fat promote atherosclerosis and elevated blood pressure
• Systemic inflammation — visceral fat is one of the primary sources of chronic, low-grade inflammation that accelerates aging
• Hormonal disruption — visceral fat contains high concentrations of aromatase, the enzyme that converts testosterone to estrogen, contributing to hormonal imbalance in both men and women
• Fatty liver disease — excess visceral fat is closely associated with non-alcoholic fatty liver disease (NAFLD)

Reducing visceral fat is one of the highest-impact interventions for cardiometabolic health, and tesamorelin has clinical evidence supporting its ability to do so.

How Tesamorelin Works

Tesamorelin is a modified version of the natural GHRH peptide (amino acids 1-44) with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification increases the peptide's stability and resistance to enzymatic degradation, making it more potent and longer-acting than native GHRH.

When injected subcutaneously, tesamorelin binds to GHRH receptors on the pituitary gland, stimulating the release of endogenous growth hormone. The resulting increase in HGH and its downstream mediator, IGF-1, produces several metabolic effects:

• Lipolysis — HGH stimulates the breakdown of stored triglycerides in adipose tissue, with a particular affinity for visceral fat depots
• Reduced lipogenesis — growth hormone inhibits the storage of new fat in visceral compartments
• Improved body composition — simultaneously supports lean muscle preservation while reducing fat mass
• Metabolic improvement — clinical studies have shown improvements in triglycerides and cholesterol profiles alongside visceral fat reduction

Clinical Evidence for Visceral Fat Reduction

Tesamorelin has been evaluated in multiple randomized, placebo-controlled clinical trials. Key findings include:

• Statistically significant reduction in trunk fat as measured by CT scan, with an average decrease of approximately 15-18% in visceral adipose tissue over 26 weeks
• Increased IGF-1 levels confirming growth hormone stimulation
• Improvements in triglyceride levels and total cholesterol-to-HDL ratio
• Trunk fat reduction was maintained with continued therapy and reversed upon discontinuation, confirming that the effect is directly attributable to the treatment

These results are notable because visceral fat is notoriously resistant to reduction through diet and exercise alone, particularly in patients with hormonal imbalances or age-related growth hormone decline.

Tesamorelin vs. Sermorelin

Both tesamorelin and sermorelin are GHRH analogs that stimulate the pituitary to release growth hormone. However, they differ in important ways:

• Potency — tesamorelin's structural modification makes it more potent and resistant to enzymatic breakdown than sermorelin
• Clinical evidence for fat reduction — tesamorelin is the only GHRH analog with FDA approval and robust clinical trial data specifically demonstrating visceral fat reduction. Sermorelin has broader anti-aging applications but less specific fat-reduction data.
• Specificity — tesamorelin is the preferred choice when visceral abdominal fat is the primary concern. Sermorelin is often preferred for general anti-aging, sleep improvement, and overall growth hormone optimization.
• Cost — tesamorelin is generally more expensive than sermorelin, reflecting its higher potency and FDA-approved status

For patients whose primary goal is visceral fat reduction, tesamorelin is the stronger option. For broader anti-aging and growth hormone optimization, sermorelin or other peptides may be more appropriate — or the two can be used sequentially.

Administration Protocol

Tesamorelin is administered as a once-daily subcutaneous injection, typically in the abdominal area. The protocol is straightforward:

• Injection type: Subcutaneous, using a small insulin-type syringe
• Frequency: Once daily, typically in the evening before bed (to align with the natural nighttime growth hormone release pattern)
• Duration: Treatment is typically continued for a minimum of 26 weeks (6 months) based on the clinical trial timeline. Longer treatment may be recommended based on response and goals.
• Monitoring: IGF-1 levels, fasting glucose, hemoglobin A1c, and body composition are tracked throughout treatment

Side Effects of Tesamorelin

• Injection site reactions — redness, itching, or mild irritation at the injection site. The most commonly reported side effect.
• Joint pain — related to growth hormone's effects on fluid and connective tissue. Usually mild and dose-dependent.
• Peripheral edema — mild swelling in the hands or feet, typically transient.
• Elevated blood sugar — growth hormone reduces insulin sensitivity. Fasting glucose and A1c are monitored during therapy.
• Headache and muscle pain — occasionally reported, usually mild.

Contraindications: Tesamorelin should not be used by patients with active cancer (growth hormone can promote cell proliferation), patients with disruption of the hypothalamic-pituitary axis due to surgery or radiation, or women who are pregnant or breastfeeding.